DIPROLENE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIPROLENE (DIPROLENE).
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins) and inhibiting release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis.
| Metabolism | Hepatic metabolism, primarily via CYP3A4. Topical absorption is minimal but can be increased with occlusive dressings or use on large areas/damaged skin. |
| Excretion | Primarily metabolized in the liver; metabolites are excreted renally and fecally. Approximately 30-40% renally, 50-60% fecally. Biliary excretion minimal. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours for the parent drug. However, due to high potency and tissue binding, clinical effects may persist longer. Context: used for short-term management. |
| Protein binding | 99.9% bound, primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 0.35 L/kg. Represents distribution mainly into extracellular fluid with some tissue binding. |
| Bioavailability | Topical: minimal systemic absorption (approximately 1-2% with intact skin, higher with damaged skin); Intramuscular: 100%; Oral: 70-80% (first-pass metabolism). |
| Onset of Action | Topical: improvement within 3-5 days; Intramuscular: 1-2 hours; Oral: 2-4 hours. |
| Duration of Action | Topical: 1-2 days after stopping; Intramuscular: 1-2 weeks; Oral: 12-24 hours duration after single dose; clinical notes: use limited to short-term due to adverse effects. |
| Molecular Weight | 534.62 |
Topical: Apply thin film to affected area once or twice daily. Maximum dose: 45 g/week.
| Dosage form | OINTMENT, AUGMENTED |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to increased systemic absorption risk. |
| Pediatric use | Safety and efficacy not established; use only if potential benefit outweighs risk. Children ≥12 years: apply once daily; maximum 15 g/week. |
| Geriatric use | No specific adjustment; use minimal effective duration due to increased skin atrophy risk. |
| 1st trimester | Avoid use due to risk of cleft palate (animal studies) and potential for fetal growth restriction. Use only if clearly needed and benefit outweighs risk. |
| 2nd trimester | Use only if clearly needed; associated with intrauterine growth restriction and adrenal suppression in fetus with prolonged or high-dose exposure. |
| 3rd trimester | Avoid prolonged or high-dose use due to risk of fetal adrenal suppression and low birth weight. |
Clinical note
Comprehensive clinical and safety monograph for DIPROLENE (DIPROLENE).
| Placental transfer | Corticosteroids cross the placenta; degree varies by compound. Betamethasone is partially metabolized by placental enzymes, reducing fetal exposure, but systemic maternal levels still lead to transfer. |
| Breastfeeding | Small amounts may appear in breast milk; not expected to cause adverse effects in infant with short-term use. Avoid application to breast area to prevent infant ingestion. Use lowest effective dose for shortest duration. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to betamethasone or any component of the formulationSystemic fungal infectionsUntreated bacterial, viral, or fungal skin infectionsApplication to broken or infected skin
| Precautions | Systemic absorption can produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., May increase risk of local infections; avoid use on infected lesions unless appropriate antimicrobial therapy is given., Prolonged use may cause atrophic changes, striae, telangiectasias, or perioral dermatitis., Use with caution on face, intertriginous areas, and in patients with impaired skin integrity. |
| Food/Dietary | No clinically significant food interactions. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Topical corticosteroids, including Diprolene (betamethasone dipropionate), have not been established as teratogenic in humans based on epidemiological studies. However, animal studies have shown teratogenicity with systemic corticosteroids. Risk cannot be ruled out; use only if potential benefit justifies risk. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression or Cushing's syndrome with prolonged use. Assess fetal growth if used extensively. No specific fetal monitoring required. |
| Fertility Effects | No specific studies on fertility effects. Systemic corticosteroids may impair fertility in animal studies; relevance to topical use is unknown. |
| Clinical Pearls | Diprolene (augmented betamethasone dipropionate) is a super-high potency topical corticosteroid. Do not use for more than 2 consecutive weeks and limit total dosage to 50 g/week due to risk of HPA axis suppression. Avoid use on face, groin, axillae, or under occlusion unless absolutely necessary. Apply sparingly to affected areas only; do not use with occlusive dressings. |
| Patient Advice | Apply a thin layer to the affected skin only, usually once or twice daily as directed. · Do not use on the face, underarms, or groin unless specifically told by your doctor. · Do not wrap or cover the treated area with bandages unless directed. · Avoid using this medication for longer than prescribed; long-term use can lead to skin thinning or adrenal problems. · Wash hands after applying unless treating the hands. · Do not use this medication on broken or infected skin unless directed. · Tell your doctor if you develop signs of infection (e.g., redness, swelling, pus) or if condition worsens. |